Patents by Inventor Christopher R. Bebbington

Christopher R. Bebbington has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibodies to EphA3
    Publication number: 20110123549
    Abstract: The current invention relates to high-affinity antibodies to EphA3 that have reduced immunogenicity when administered to a human to treat diseases and method of using such antibodies.
    Type: Application
    Filed: October 14, 2010
    Publication date: May 26, 2011
    Applicant: KaloBios Pharmaceuticals, Inc.
    Inventors: Kenneth Luehrsen, David Martinez, Christina Yi, Christopher R. Bebbington, Geoffrey T. Yarranton
  • Methods for the therapy of Inflammatory Bowel Disease using a type-1 interferon antagonist
    Patent number: 7939076
    Abstract: Compositions and methods for the therapy of Inflammatory Bowel Disease (IBD), including Celiac Disease, Crohn's Disease, and Ulcerative Colitis, are disclosed. Illustrative compositions comprise one or more anti-type 1 interferon antagonists, such as anti-type 1 interferon receptor antibody antagonists and fragments thereof, as well as polypeptides and small molecules that inhibit the interaction of type 1 interferon with its receptor (IFNAR).
    Type: Grant
    Filed: April 23, 2004
    Date of Patent: May 10, 2011
    Assignee: Medarex, Inc.
    Inventors: Lesley B. Pickford, Christopher R. Bebbington, Geoffrey T. Yarranton, David King
  • HUMANIZED ANTIBODIES TO INTERFERON ALPHA RECEPTOR-1 (IFNAR-1)
    Publication number: 20110086422
    Abstract: Humanized monoclonal antibodies which bind to IFNAR-1, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the humanized antibodies and therapeutic and diagnostic methods for using the humanized antibodies.
    Type: Application
    Filed: December 20, 2010
    Publication date: April 14, 2011
    Inventors: Josephine M. Cardarelli, Tseng-hui Timothy Chen, David King, Christopher R. Bebbington, Sarah Lee Pogue, Francis J. Carr, Stephen Williams
  • Humanized antibodies to interferon alpha receptor-1 (IFNAR-1)
    Patent number: 7888484
    Abstract: Humanized monoclonal antibodies which bind to IFNAR-1, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the humanized antibodies and therapeutic and diagnostic methods for using the humanized antibodies.
    Type: Grant
    Filed: September 29, 2009
    Date of Patent: February 15, 2011
    Assignee: Medarex, Inc.
    Inventors: Josephine M. Cardarelli, Tseng-hui Timothy Chen, David King, Christopher R. Bebbington, Sarah Lee Pogue, Francis J. Carr, Stephen Williams
  • COMBINATION ANTIBIOTIC AND ANTIBODY THERAPY FOR THE TREATMENT OF PSEUDOMONAS AERUGINOSA INFECTION
    Publication number: 20100272736
    Abstract: The present invention provides improved pharmaceutical compositions and methods of treating or preventing development of bacteremia associated with Pseudomonas aeruginosa infections, where the method comprises administering an antibiotic and an anti-PcrV antibody.
    Type: Application
    Filed: February 4, 2010
    Publication date: October 28, 2010
    Applicants: KaloBios Pharmaceuticals, Inc., The Regents of the University of California
    Inventors: Mark Baer, Christopher R. Bebbington, Geoffrey T. Yarranton, Susan Lynch, Yuanlin Song
  • Tripeptide prodrug compounds
    Patent number: 7816317
    Abstract: The prodrug of the invention is a modified form of a therapeutic agent and comprises a therapeutic agent, an oligopeptide of three amino acids, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by a trouase enzyme such as Thimet oligopeptidase. Also disclosed are methods of making and using the prodrug compounds.
    Type: Grant
    Filed: March 27, 2007
    Date of Patent: October 19, 2010
    Assignee: Medarex, Inc.
    Inventors: Christopher R. Bebbington, Vincent Dubois, Sanjeev Gangwar, Thomas J. Lobl, Matthew H. Nieder, Lesley B. Pickford, Andre Trouet, Geoffrey T. Yarranton
  • Treatment of Leukemias and Chronic Myeloproliferative Diseases with Antibodies to EphA3
    Publication number: 20100226930
    Abstract: The invention provides methods and compositions comprising anti-EphA3 antibodies for the treatment of myeloproliferative disorders.
    Type: Application
    Filed: March 5, 2010
    Publication date: September 9, 2010
    Applicant: KaloBios Pharmaceuticals, Inc.
    Inventors: Christopher R. Bebbington, Geoffrey T. Yarranton, Varghese Palath
  • METHODS OF TREATING DEMENTIA USING A GM-CSF ANTAGONIST
    Publication number: 20100215650
    Abstract: The invention is based on the discovery that GM-CSF antagonists can be used for the treatment of a patient that has Alzheimer's disease or vascular dementia, or is at risk for developing Alzheimer's disease. Accordingly, the invention provides methods of administering a GM-CSF antagonist, e.g., a GM-CSF antibody and pharmaceutical compositions comprising such antagonists.
    Type: Application
    Filed: February 11, 2010
    Publication date: August 26, 2010
    Applicant: KaloBios Pharmaceuticals, Inc.
    Inventors: Christopher R. Bebbington, Geoffrey T. Yarranton, Varghese Palath
  • CD10-activated prodrug compounds
    Patent number: 7771962
    Abstract: The compounds of the invention are modified forms of therapeutic agents. A typical prodrug compound of the invention comprises a therapeutic agent, an oligopeptide, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by the CD10 enzyme. Methods of treatment using the prodrug and methods of designing the prodrug are also disclosed.
    Type: Grant
    Filed: November 20, 2007
    Date of Patent: August 10, 2010
    Assignee: Medarex, Inc.
    Inventors: Christopher R. Bebbington, Matthew H. Nieder, Pina M. Cardarelli, Sanjeev Gangwar, Lesley B. Pickford, Chin Pan
  • Vector
    Patent number: 7718627
    Abstract: A vector comprising a nucleotide sequence of interest (“NOI”) encoding a product of interest (“POI”) is described. The NOI and/or the POI is capable of recognizing a tumor, such that in use the vector is capable of delivering the NOI and/or the POI to the tumor.
    Type: Grant
    Filed: April 25, 2006
    Date of Patent: May 18, 2010
    Assignee: Oxford Biomedica (UK) Limited
    Inventors: Susan M. Kingsman, Christopher R. Bebbington, Fiona M. Ellard, Miles W. Carroll, Kevin A. Myers
  • HUMANIZED ANTIBODIES TO INTERFERON ALPHA RECEPTOR-1 (IFNAR-1)
    Publication number: 20100104569
    Abstract: Humanized monoclonal antibodies which bind to IFNAR-1, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the humanized antibodies and therapeutic and diagnostic methods for using the humanized antibodies.
    Type: Application
    Filed: September 29, 2009
    Publication date: April 29, 2010
    Applicant: MEDAREX, INC.
    Inventors: Josephine M. Cardarelli, Tseng-hui Timothy Chen, David King, Christopher R. Bebbington, Sarah Lee Pogue, Francis J. Carr, Stephen Williams
  • Humanized antibodies to interferon alpha receptor-1 (IFNAR-1)
    Patent number: 7619070
    Abstract: Humanized monoclonal antibodies which bind to IFNAR-1, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the humanized antibodies and therapeutic and diagnostic methods for using the humanized antibodies.
    Type: Grant
    Filed: April 23, 2004
    Date of Patent: November 17, 2009
    Assignee: Medarex, Inc.
    Inventors: Josephine M. Cardarelli, Tseng-Hui Timothy Chen, David J. King, Christopher R. Bebbington, Sarah Lee Pogue, Francis J. Carr, Stephen Williams
  • ANTIBODIES TO GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR
    Publication number: 20090274706
    Abstract: The current invention relates to high-affinity antibodies to Granulocyte-Macrophage Colony-Stimulating Factor that have reduced immunogenicity when administered to a human to treat diseases and method of using such antibodies.
    Type: Application
    Filed: April 28, 2009
    Publication date: November 5, 2009
    Applicant: Kalobios Pharmaceuticals, Inc.
    Inventors: Christopher R. Bebbington, Kenneth Luehrsen, Geoffrey T. Yarranton
  • Neutralization of GM-CSF for the Treatment of Heart Failure
    Publication number: 20090263387
    Abstract: This invention relates to methods of treating a patient suffering from heart failure, or a patient at risk for heart failure, using a GM-CSF antagonist.
    Type: Application
    Filed: April 7, 2009
    Publication date: October 22, 2009
    Applicant: KaloBios Pharmaceuticals, Inc.
    Inventors: Christopher R. Bebbington, Geoffrey T. Yarranton
  • Antibodies to the PcrV Antigen of Pseudomonas aeruginosa
    Publication number: 20090191186
    Abstract: The current invention provides high-affinity antibodies to the Pseudomonas aeruginosa PcrV protein that have reduced immunogenicity when administered to treat Pseudomonas aeruginosa infections.
    Type: Application
    Filed: December 1, 2008
    Publication date: July 30, 2009
    Applicant: KaloBios Pharmaceuticals, Inc.
    Inventors: Christopher R. Bebbington, Kenneth Luehrsen, Geoffrey T. Yarranton, Mark Baer
  • Methods of Treating Bone-Loss Disorders Using a GM-CSF Antagonist
    Publication number: 20090181020
    Abstract: The invention is based on the discovery that GM-CSF antagonists can be used for the treatment of bone loss disorders, such as osteopenia. Accordingly, the invention provides methods of administering a GM-CSF antagonist, e.g., a GM-CSF antibody, to a patient that has a bone loss disorder and pharmaceutical compositions comprising such antagonists.
    Type: Application
    Filed: January 15, 2009
    Publication date: July 16, 2009
    Applicant: KaloBios Pharmaceuticals, Inc.
    Inventors: Christopher R. BEBBINGTON, Geoffrey T. Yarranton
  • CD10-activated prodrug compounds
    Publication number: 20090136980
    Abstract: The compounds of the invention are modified forms of therapeutic agents. A typical prodrug compound of the invention comprises a therapeutic agent, an oligopeptide, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by the CD10 enzyme. Methods of treatment using the prodrug and methods of designing the prodrug are also disclosed.
    Type: Application
    Filed: November 20, 2007
    Publication date: May 28, 2009
    Applicant: MEDAREX, INC.
    Inventors: Christopher R. Bebbington, Matthew H. Nieder, Pina M. Cardarelli, Sanjeev Gangwar, Lesley B. Pickford, Chin Pan
  • Antibodies
    Patent number: 7514546
    Abstract: The use of an ScFv Ab (ScFv Ab) capable of recognizing a disease associated molecule (DAM) in the manufacture of a medicament for the prevention and/or treatment of a disease condition associated with a DAM is described. The ScFv Ab has therapeutic, diagnostic and prognostic applications.
    Type: Grant
    Filed: April 26, 2006
    Date of Patent: April 7, 2009
    Assignee: Oxford BioMedica (UK) Ltd.
    Inventors: Susan Mary Kingsman, Christopher R. Bebbington, Miles W. Carroll, Fiona M. Ellard, Kevin A. Myers
  • EphA3 Antibodies for the Treatment of Solid Tumors
    Publication number: 20080286272
    Abstract: The invention provides methods and compositions comprising anti-EphA3 antibodies for the treatment of solid tumors.
    Type: Application
    Filed: March 10, 2008
    Publication date: November 20, 2008
    Applicants: KaloBios Pharmaceuticals, Inc., Ludwig Institute for Cancer Research, Monash University
    Inventors: Martin Lackmann, Andrew Mark Scott, Christopher R. Bebbington, Geoffrey T. Yarranton, Carmelina Murone, Catherine To
  • Methods of Treating Chronic Inflammatory Diseases Using a GM-CSF Antagonist
    Publication number: 20080206241
    Abstract: The invention is based on the discovery that GM-CSF antagonists can be used for the treatment of chronic inflammatory disease, such as rheumatoid arthritis. Accordingly, the invention provides methods of administering a GM-CSF antagonist, e.g., a GM-CSF antibody, and an anti-folate compounds, e.g., methotrexate, to a patient that has RA and pharmaceutical compositions comprising such antagonists.
    Type: Application
    Filed: November 21, 2007
    Publication date: August 28, 2008
    Applicant: KaloBios Pharmaceuticals Inc.
    Inventors: Christopher R. Bebbington, Geoffrey T. Yarranton